Benitec FY2026: $180M Cash, BB-301 Cohort 2 Fully Enrolled, FDA Pivotal Design Discussed

summarizeSummary

FY2026 results included $180M cash, completed Cohort 1 follow-up, fully enrolled Cohort 2, and an FDA Type C meeting on BB-301 pivotal design. Interim data will be presented at ESGCT in late October.

check_boxKey Events · Earnings and Guidance · BNTC

• FY2026 Financial Results

  Net loss of $45.5M ($0.98/share) vs $37.9M ($1.05/share) in FY2025; total operating expenses rose to $51.2M from $41.8M, driven by higher share-based compensation and payroll.

• Cash Position

  $180.0M in cash and cash equivalents as of June 30, 2026, up from $97.7M a year earlier, providing runway well beyond the planned mid-2027 pivotal trial initiation.

• BB-301 Clinical Progress

  All six Cohort 1 (low dose) patients completed 12-month follow-up; Cohort 2 (high dose) fully enrolled with all three patients safely treated. Clinically meaningful improvements observed in swallowing function.

• FDA Regulatory Milestone

  Type C meeting held with FDA in 3Q2026 to discuss BB-301 pivotal study design; meeting minutes anticipated in October 2026.

auto_awesomeAnalysis · BNTC · Life Sciences

A year of clinical execution for BB-301 has positioned Benitec for a pivotal study: all six low-dose patients completed 12-month follow-up, the high-dose cohort is fully enrolled and safely treated, and a Type C FDA meeting has set the stage for the pivotal design, with minutes due in October. The company holds $180 million in cash against a $51.2 million annual operating loss, funding operations well past the planned mid-2027 pivotal trial initiation. The net loss widened to $45.5 million from $37.9 million, driven by higher share-based compensation and payroll, but the balance sheet remains strong with no near-term financing risk. Interim data accepted for late-breaking presentation at ESGCT in late October provides the next concrete readout.